Brand names: FASENRA
Benralizumab is indicated for:
Severe eosinophilic asthma
Irrespective of gender only Adults (18 years old or older)
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Subcutaneous - 30 mg once every 4 weeks
Active ingredient Benralizumab is contraindicated in the following cases: